This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ICPT Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Intercept Pharmaceuticals Stock (NASDAQ:ICPT) Get ICPT alerts:Sign Up Key Stats Today's Range$19.00▼$19.0050-Day Range$18.20▼$19.0052-Week Range$8.82▼$21.86VolumeN/AAverage Volume1.36 million shsMarket Capitalization$794.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A.. Read More Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ICPT Stock News HeadlinesIntercept Pharma pulls liver disease drug from US after regulator's requestSeptember 11, 2025 | msn.comIntercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical ...September 11, 2025 | markets.businessinsider.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 2 at 1:00 AM | InvestorPlace (Ad)Intercept Pharma withdraws liver disease drug from US marketSeptember 11, 2025 | reuters.comIntercept Announces Data to be Presented at Digestive Disease Week 2025April 30, 2025 | finance.yahoo.comIntercept loses Ocaliva FDA full approval bid in rare liver diseaseNovember 13, 2024 | msn.comUS FDA declines full approval for Intercept's liver disease drugNovember 12, 2024 | reuters.comIntercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)November 12, 2024 | globenewswire.comSee More Headlines ICPT Stock Analysis - Frequently Asked Questions How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.42. The firm's revenue for the quarter was up 16.6% on a year-over-year basis. Read the conference call transcript. When did Intercept Pharmaceuticals IPO? Intercept Pharmaceuticals (ICPT) raised $70 million in an initial public offering (IPO) on Thursday, October 11th 2012. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Sarepta Therapeutics (SRPT), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings8/02/2023Today6/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ICPT CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees341Year Founded2002Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins-19.39% Pretax Margin-18.09% Return on Equity-77.48% Return on Assets-11.99% Debt Debt-to-Equity Ratio3.12 Current Ratio4.22 Quick Ratio2.52 Sales & Book Value Annual Sales$285.71 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book11.05Miscellaneous Outstanding Shares41,830,000Free Float39,192,000Market Cap$794.77 million OptionableNo Data Beta0.88 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ICPT) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredI stumbled into this at 3 PMEvery trading day, $55 billion floods the market in the final hour between 3 and 4 PM Eastern. One trader noti...Trade To Close | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intercept Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
